TY - JOUR
T1 - Real-world data for health technology assessment for reimbursement decisions in Asia
T2 - Current landscape and a way forward
AU - Lou, Jing
AU - Kc, Sarin
AU - Toh, Kai Yee
AU - Dabak, Saudamini
AU - Adler, Amanda
AU - Ahn, Jeonghoon
AU - Bayani, DIana Beatriz S.
AU - Chan, Kelvin
AU - Choiphel, Dechen
AU - Chua, Brandon
AU - Genuino, Anne Julienne
AU - Guerrero, Anna Melissa
AU - Kearney, Brendon
AU - Lin, Lydia Wenxin
AU - Liu, Yuehua
AU - Nakamura, Ryota
AU - Pearce, Fiona
AU - Prinja, Shankar
AU - Pwu, Raoh Fang
AU - Shafie, Asrul Akmal
AU - Sui, Binyan
AU - Suwantika, Auliya
AU - Teerawattananon, Yot
AU - Tunis, Sean
AU - Wu, Hui Min
AU - Zalcberg, John
AU - Zhao, Kun
AU - Isaranuwatchai, Wanrudee
AU - Wee, Hwee Lin
N1 - Publisher Copyright:
Copyright © The Author(s), 2020. Published by Cambridge University Press.
PY - 2020/10
Y1 - 2020/10
N2 - There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for health technology assessment (HTA). Optimal collection, analysis, and use of RWD/RWE to inform HTA requires a conceptual framework to standardize processes and ensure consistency. However, such framework is currently lacking in Asia, a region that is likely to benefit from RWD/RWE for at least two reasons. First, there is often limited Asian representation in clinical trials unless specifically conducted in Asian populations, and RWD may help to fill the evidence gap. Second, in a few Asian health systems, reimbursement decisions are not made at market entry; thus, allowing RWD/RWE to be collected to give more certainty about the effectiveness of technologies in the local setting and inform their appropriate use. Furthermore, an alignment of RWD/RWE policies across Asia would equip decision makers with context-relevant evidence, and improve timely patient access to new technologies. Using data collected from eleven health systems in Asia, this paper provides a review of the current landscape of RWD/RWE in Asia to inform HTA and explores a way forward to align policies within the region. This paper concludes with a proposal to establish an international collaboration among academics and HTA agencies in the region: the REAL World Data In ASia for HEalth Technology Assessment in Reimbursement (REALISE) working group, which seeks to develop a non-binding guidance document on the use of RWD/RWE to inform HTA for decision making in Asia.
AB - There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for health technology assessment (HTA). Optimal collection, analysis, and use of RWD/RWE to inform HTA requires a conceptual framework to standardize processes and ensure consistency. However, such framework is currently lacking in Asia, a region that is likely to benefit from RWD/RWE for at least two reasons. First, there is often limited Asian representation in clinical trials unless specifically conducted in Asian populations, and RWD may help to fill the evidence gap. Second, in a few Asian health systems, reimbursement decisions are not made at market entry; thus, allowing RWD/RWE to be collected to give more certainty about the effectiveness of technologies in the local setting and inform their appropriate use. Furthermore, an alignment of RWD/RWE policies across Asia would equip decision makers with context-relevant evidence, and improve timely patient access to new technologies. Using data collected from eleven health systems in Asia, this paper provides a review of the current landscape of RWD/RWE in Asia to inform HTA and explores a way forward to align policies within the region. This paper concludes with a proposal to establish an international collaboration among academics and HTA agencies in the region: the REAL World Data In ASia for HEalth Technology Assessment in Reimbursement (REALISE) working group, which seeks to develop a non-binding guidance document on the use of RWD/RWE to inform HTA for decision making in Asia.
KW - Asia
KW - Cost-effectiveness analysis
KW - Health technology assessment
KW - Real-world data
KW - Real-world evidence
UR - http://www.scopus.com/inward/record.url?scp=85096157673&partnerID=8YFLogxK
U2 - 10.1017/S0266462320000628
DO - 10.1017/S0266462320000628
M3 - Review article
C2 - 32928330
AN - SCOPUS:85096157673
SN - 0266-4623
VL - 36
SP - 474
EP - 480
JO - International Journal of Technology Assessment in Health Care
JF - International Journal of Technology Assessment in Health Care
IS - 5
ER -